Inhibition of hyperreflexia by vaginally administered oxybutynin: A novel rabbit model

Journal of Urology

Volumn 171, Issue 2 I, 2004, Pages 958-962

  Chou, Eric Chieh Lung ^a,e   Whitbeck, Catherine ^a,b   Borow, Abby ^d   Burden, Opal ^c   Levin, Robert M ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

^c Department of Special Education and Literacy   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acetylcholine; Bladder; Oxybutynin; Rabbits

Indexed keywords

ACETYLCHOLINE; OXYBUTYNIN;

ANIMAL MODEL; ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER CONTRACTION; BLADDER INSTABILITY; BLADDER NECK STENOSIS; BLADDER PRESSURE; BLOOD PRESSURE MONITORING; CAROTID ARTERY; CONTROLLED STUDY; CYSTOMETRY; ERECTILE DYSFUNCTION; FEMALE; HYPERREFLEXIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RABBIT; URETHRA DISEASE; URETHRA FUNCTION;

EID: 0346498106     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000092557.02298.da     Document Type: Article

References (18)

1. Anderson, K. E.: Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev, 45: 253, 1993
2. Steers, W. D.: Physiology of the urinary bladder. In: Campbell's Urology, 6th ed. Edited by P. C. Walsh, A. B. Retik, T. A. Stamey and E. D. Vaughan, Jr. Philadelphia: W. B. Saunders Co., vol. 1. chapt. 6, p. 142, 1992
3. Zderic, S. A., Levin, R. M. and Wein, A. J.: Voiding function and dysfunction. A. Voiding function: relevant anatomy, physiology, pharmacology, and molecular aspects. In: Adult and Pediatric Urology, 3rd ed. Edited by J. Y. Gillenwater, J. T. Grayhack, S. S. Howards and J. W. Duckett. Chicago: Mosby-Year Book, Inc., part I, pp. 1159-1219, 1996
4. Andersson, K. E.: Overactive bladder-pharmacological aspects. Scand J Urol Nephrol, suppl., 210: 72, 2002
5. Garnett, S. and Abrams, P.: Clinical aspects of the overactive bladder and detrusor overactivity. Scand J Urol Nephrol, suppl., 210: 65, 2002
6. Jabs, C. F. and Stanton, S. L.: Urge incontinence and detrusor instability. Int Urogynecol J Pelvic Floor Dysfunct, 12: 58, 2001
7. Anderson, R. U., Mobley, D., Blank, B., Saltzstein, D., Susset, J., Brown, J. S. et al: Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol, 161: 1809, 1999
8. Gupta, S. K. and Sathyan, G.: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol, 39: 289, 1999
9. Gupta, S. K., Sathyan, G., Lindemulder, E. A., Ho, P. L., Sheiner, L. B. and Aarons, L.: Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther, 65: 672, 1999
10. Levin, R. M. and Wein, A. J.: Direct measurement of the anticholinergic activity of a series of pharmacological compounds on the canine and rabbit urinary bladder. J Urol, 128: 396, 1982
11. Wein, A. J.: Pharmacologic options for the overactive bladder. Urology, suppl., 51: 43, 1998
12. Versi, E., Appell, R., Mobley, D., Patton, W. and Saltzstein, D.: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol, 95: 718, 2000
13. Comer, A. M. and Goa, K. L.: Extended-release oxybutynin. Drugs Aging, 16: 149, 2000
14. Schroder, A., Levin, R. M., Kogan, B. A., Kay, F. and Mahashabde, A.: Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology, 56: 1063, 2000
15. Levin, R. M., Whitbeck, C., Borow, A., Burden, O. and Leggett, R. E: Effectiveness of vaginally administered oxybutynin on rabbit bladder function. Urology, 61: 1273, 2003
16. Liu, S.-P., Horan, P. and Levin, R. M.: Effects of atropine, isoproterenol and propranolol on the rabbit bladder contraction induced by intra-arterial administration of acetylcholine and ATP. J Urol, 160: 1863, 1998
17. Swithinbank, L. and Abrams, P.: Lower urinary tract symptoms in community-dwelling women: defining diurnal and nocturnal frequency and 'the incontinence case'. BJU Int, suppl., 88: 18, 2001
18. Buyse, G., Waldeck, K., Verpoorten, C., Björk, H., Casaer, P. and Andersson, K.-E.: Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol, 160: 892, 1998